Sibutramine-associated adverse effects: A practical guide for its safe use

Obesity Reviews

Volumn 9, Issue 4, 2008, Pages 378-387

  Florentin, M ^a   Liberopoulos, E N ^a   Elisaf, M S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Blood pressure; Pulse rate; Sibutramine; Side effects

Indexed keywords

CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOPROLOL; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PLACEBO; SIBUTRAMINE; THIAZIDE DIURETIC AGENT;

ABNORMAL DREAMING; ABNORMAL THINKING; ABNORMAL VISION; ADULT; AGITATION; ALOPECIA; AMBLYOPIA; AMNESIA; ANAPHYLACTIC SHOCK; ANAPHYLAXIS; ANEMIA; ANGER; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ANOVULATION; ARTHRITIS; AUDITORY HALLUCINATION; BEHAVIOR CHANGE; BLURRED VISION; BRONCHITIS; CALORIC INTAKE; CALORIC RESTRICTION; CEREBROVASCULAR ACCIDENT; CHEST TIGHTNESS; CHILD; CHOLECYSTITIS; CHOLELITHIASIS; CLINICAL TRIAL; CONCENTRATION LOSS; CONFUSION; DELUSION; DELUSION OF REFERENCE; DEPRESSION; DERMATITIS; DIALYSIS; DIARRHEA; DIZZINESS; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRY EYE; DUODENUM ULCER; DYSPNEA; EJACULATION DISORDER; ERUCTATION; EXTERNAL OTITIS; EYE PAIN; FACE EDEMA; FAINTNESS; FEVER; FLATULENCE; GAIT DISORDER; GASTROENTERITIS; GASTROINTESTINAL HEMORRHAGE; GILLES DE LA TOURETTE SYNDROME; GOITER; HEADACHE; HEART ARRHYTHMIA; HEART FAILURE; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HEMATURIA; HEPATITIS; HUMAN; HYPERGLYCEMIA; HYPERSALIVATION; HYPERTENSION; HYPERTHYROIDISM; HYPESTHESIA; HYPOGLYCEMIA; HYPOMANIA; HYPOTHYROIDISM; IMPOTENCE; INCREASED LIBIDO; INSOMNIA; INTERSTITIAL NEPHRITIS; INTESTINE OBSTRUCTION; INTRAOCULAR PRESSURE; LEG CRAMP; LEUKOPENIA; LIBIDO DISORDER; LIFESTYLE; LIFESTYLE MODIFICATION; LIVER INJURY; LYMPHADENOPATHY; MANIA; MEDLINE; MENSTRUATION DISORDER; MICTURITION DISORDER; MOOD CHANGE; MOUTH ULCER; MUSCLE HYPERTONIA; NIGHTMARE; OBESITY; OTITIS MEDIA; PANIC; PARANOIA; PERIPHERAL EDEMA; PETECHIA; PHOTOSENSITIVITY; PRURITUS; QT PROLONGATION; RASH; RESPIRATORY TRACT DISEASE; REVIEW; SEROTONIN SYNDROME; SIDE EFFECT; SITTING; SPEECH DISORDER; STOMACH ULCER; SUDDEN DEAFNESS; SUICIDE ATTEMPT; SUPRAVENTRICULAR TACHYCARDIA; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; TINNITUS; TONGUE EDEMA; TOOTH DISOR; TRANSIENT ISCHEMIC ATTACK; URINARY FREQUENCY; URINE RETENTION; URTICARIA; WEIGHT REDUCTION;

APPETITE DEPRESSANTS; CYCLOBUTANES; HEART RATE; HUMANS; HYPERTENSION; OBESITY; RISK ASSESSMENT; SAFETY;

EID: 45249109128     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/j.1467-789X.2007.00425.x     Document Type: Review

References (95)

1. Solomon CG, Manson JE. Obesity and mortality: a review of the epidemiologic data. Am J Clin Nutr 1997 66 : 1044S 1050S.
2. Klein S, Burke LE, Bray GA, Blair S, Allison DB, Pi-Sunyer X, Hong Y, Eckel RH. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004 110 : 2952 2967.
3. Pi-Sunyer FX. The epidemiology of central fat distribution in relation to disease. Nutr Rev 2004 62 : S120 S126.
4. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002 288 : 1723 1727.
5. Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA 2002 288 : 1728 1732.
6. Halford JC. Clinical pharmacotherapy for obesity: current drugs and those in advanced development. Curr Drug Targets 2004 5 : 637 646.
7. Liberopoulos EN, Mikhailidis DP, Elisaf MS. Diagnosis and management of the metabolic syndrome in obesity. Obes Rev 2005 6 : 283 296.
8. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 346 : 393 403.
9. Liberopoulos EN, Tsouli S, Mikhailidis DP, Elisaf MS. Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr Drug Targets 2006 7 : 211 228.
10. Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, Smith WC, Jung RT, Campbell MK, Grant AM. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004 8 : iii iv, 1 182.
11. Wadden TA, Butryn ML. Behavioral treatment of obesity. Endocrinol Metab Clin North Am 2003 32 : 981 1003, x.
12. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007 369 : 71 77.
13. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004 164 : 994 1003.
14. Jackson HC, Bearham MC, Hutchins LJ, Mazurkiewicz SE, Needham AM, Heal DJ. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br J Pharmacol 1997 121 : 1613 1618.
15. Luscombe GP, Hopcroft RH, Thomas PC, Buckett WR. The contribution of metabolites to the rapid and potent down-regulation of rat cortical beta-adrenoceptors by the putative antidepressant sibutramine hydrochloride. Neuropharmacology 1989 28 : 129 134.
16. McNeely W, Goa KL. Sibutramine. A review of its contribution to the management of obesity. Drugs 1998 56 : 1093 1124.
17. Finer N. Sibutramine: its mode of action and efficacy. Int J Obes Relat Metab Disord 2002 26 : S29 S33.
18. Lean ME. How does sibutramine work? Int J Obes Relat Metab Disord 2001 25 : S8 S11.
19. Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JL. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA 2003 289 : 1805 1812.
20. Serrano-Rios M, Melchionda N, Moreno-Carretero E. Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy. Diabet Med 2002 19 : 119 124.
21. Gokcel A, Gumurdulu Y, Karakose H, Melek Ertorer E, Tanaci N, BascilTutuncu N, Guvener N. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab 2002 4 : 49 55.
22. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, Hilton L, Suttorp M, Solomon V, Shekelle PG, Morton SC. Meta-analysis. Pharmacologic treatment of obesity. Ann Intern Med 2005 142 : 532 546.
23. Henderson DC, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD, Louie PM, Evins AE, Freudenreich O, Hayden D, Goff DC. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry 2005 162 : 954 962.
24. Henderson DC, Fan X, Copeland PM, Borba CP, Daley TB, Nguyen DD, Zhang H, Hayden D, Freudenreich O, Cather C, Evins AE, Goff DC. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr Scand 2007 115 : 101 105.
25. Alisky JM. Phentermine, sibutramine and metformin could be used for the prevention and treatment of steroid-induced weight gain. Med Hypotheses 2007 68 : 460 461.
26. Kiortsis DN, Tsouli S, Filippatos TD, Konitsiotis S, Elisaf MS. Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study. Nutr Metab Cardiovasc Dis 2007 12 June [Epub ahead of print].
27. Wang TF, Pei D, Li JC, Tsai WC, Tsai CC, Yao CY, Chang ET, Hsieh MC, Su KY, Kuo SW. Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study. Int J Clin Pract 2005 59 : 746 750.
28. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, Saris WH, Van Gaal LF. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine trial of obesity reduction and maintenance. Lancet 2000 356 : 2119 2125.
29. Torp-Pedersen C, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, Sharma A, Brisco W, Deaton R, Shepherd G, James P. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007 26 June [Epub ahead of print].
30. Sabuncu T, Harma M, Harma M, Nazligul Y, Kilic F. Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome. Fertil Steril 2003 80 : 1199 1204.
31. Sabuncu T, Nazligul Y, Karaoglanoglu M, Ucar E, Kilic FB. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Rom J Gastroenterol 2003 12 : 189 192.
32. Diakou MC, Liberopoulos EN, Mikhailidis DP, Tsianos EV, Burroughs AK, Elisaf MS. Pharmacological treatment of non-alcoholic steatohepatitis: the current evidence. Scand J Gastroenterol 2007 42 : 139 147.
33. Yee BJ, Phillips CL, Banerjee D, Caterson I, Hedner JA, Grunstein RR. The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea. Int J Obes (Lond) 2007 31 : 161 168.
34. Martinez D, Basile BR. Sibutramine does not worsen sleep apnea syndrome: a randomized double-blind placebo-controlled study. Sleep Med 2005 6 : 467 470.
35. Milano W, Petrella C, Casella A, Capasso A, Carrino S, Milano L. Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: a placebo-controlled study. Adv Ther 2005 22 : 25 31.
36. Appolinario JC, Bacaltchuk J, Sichieri R, Claudino AM, Godoy-Matos A, Morgan C, Zanella MT, Coutinho W. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. Arch Gen Psychiatry 2003 60 : 1109 1116.
37. Appolinario JC, Godoy-Matos A, Fontenelle LF, Carraro L, Cabral M, Vieira A, Coutinho W. An open-label trial of sibutramine in obese patients with binge-eating disorder. J Clin Psychiatry 2002 63 : 28 30.
38. Filippatos TD, Kiortsis DN, Liberopoulos EN, Mikhailidis DP, Elisaf MS. A review of the metabolic effects of sibutramine. Curr Med Res Opin 2005 21 : 457 468.
39. Leung WY, Thomas GN, Chan JC, Tomlinson B. Weight management and current options in pharmacotherapy: orlistat and sibutramine. Clin Ther 2003 25 : 58 80.
40. Kamel EG, McNeill G, Van Wijk MC. Change in intra-abdominal adipose tissue volume during weight loss in obese men and women: correlation between magnetic resonance imaging and anthropometric measurements. Int J Obes Relat Metab Disord 2000 24 : 607 613.
41. Van Gaal LF, Wauters MA, Peiffer FW, De Leeuw IH. Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction?. Int J Obes Relat Metab Disord 1998 22 : S38 S40.
42. Porter JA, Raebel MA, Conner DA, Lanty FA, Vogel EA, Gay EC, Merenich JA. The long-term outcomes of sibutramine effectiveness on weight (LOSE weight) study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization. Am J Manag Care 2004 10 : 369 376.
43. Gazi I, Liberopoulos E, Mikhailidis DP, Elisaf M. Metabolic syndrome: clinical features leading to therapeutic strategies. Vasc Dis Prevent 2004 1 : 243 253.
44. Krejs GJ. Metabolic benefits associated with sibutramine therapy. Int J Obes Relat Metab Disord 2002 26 : S34 S37.
45. Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab 2000 2 : 105 112.
46. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Kim C, Lau J. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med 2004 164 : 1395 1404.
47. Sanchez-Reyes L, Fanghanel G, Yamamoto J, Martinez-Rivas L, Campos-Franco E, Berber A. Use of sibutramine in overweight adult Hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial. Clin Ther 2004 26 : 1427 1435.
48. Sabuncu T, Ucar E, Birden F, Yasar O. The effect of 1-year sibutramine treatment on glucose tolerance, insulin sensitivity and serum lipid profiles in obese subjects. Diabetes Nutr Metab 2004 17 : 103 107.
49. McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 2002 16 : 5 11.
50. Tambascia MA, Geloneze B, Repetto EM, Geloneze SR, Picolo M, Magro DO. Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial. Diabetes Obes Metab 2003 5 : 338 344.
51. Valsamakis G, McTernan PG, Chetty R, Al Daghri N, Field A, Hanif W, Barnett AH, Kumar S. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 2004 53 : 430 434.
52. McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, Johnson F, Mooradian AD. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000 160 : 2185 2191.
53. Fujioka K, Seaton TB, Rowe E, Jelinek CA, Raskin P, Lebovitz HE, Weinstein SP. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2000 2 : 175 187.
54. Kim SH, Lee YM, Jee SH, Nam CM. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res 2003 11 : 1116 1123.
55. Ersoz HO, Ukinc K, Baykan M, Erem C, Durmus I, Hacihasanoglu A, Telatar M. Effect of low-dose metoprolol in combination with sibutramine therapy in normotensive obese patients: a randomized controlled study. Int J Obes Relat Metab Disord 2004 28 : 378 383.
56. Sramek JJ, Leibowitz MT, Weinstein SP, Rowe ED, Mendel CM, Levy B, McMahon FG, Mullican WS, Toth PD, Cutler NR. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. J Hum Hypertens 2002 16 : 13 19.
57. Berube-Parent S, Prud'homme D, St-Pierre S, Doucet E, Tremblay A. Obesity treatment with a progressive clinical tri-therapy combining sibutramine and a supervised diet - exercise intervention. Int J Obes Relat Metab Disord 2001 25 : 1144 1153.
58. Fanghanel G, Cortinas L, Sanchez-Reyes L, Gomez-Santos R, Campos-Franco E, Berber A. Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension. Adv Ther 2003 20 : 101 113.
59. Derosa G, Cicero AF, Murdolo G, Piccinni MN, Fogari E, Bertone G, Ciccarelli L, Fogari R. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes Obes Metab 2005 7 : 47 55.
60. Ohkubo T. Prognostic significance of variability in ambulatory and home blood pressure from the ohasama study. J Epidemiol 2007 17 : 109 113.
61. Sharma AM. Sibutramine in overweight/obese hypertensive patients. Int J Obes Relat Metab Disord 2001 25 : S20 S23.
62. Reil JC, Bohm M. The role of heart rate in the development of cardiovascular disease. Clin Res Cardiol 2007 96 : 585 592.
63. Birkenfeld AL, Schroeder C, Boschmann M, Tank J, Franke G, Luft FC, Biaggioni I, Sharma AM, Jordan J. Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation 2002 106 : 2459 2465.
64. Birkenfeld AL, Schroeder C, Pischon T, Tank J, Luft FC, Sharma AM, Jordan J. Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients - sibutramine and blood pressure. Clin Auton Res 2005 15 : 200 206.
65. Schroeder C, Tank J, Boschmann M, Diedrich A, Sharma AM, Biaggioni I, Luft FC, Jordan J. Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance. Circulation 2002 105 : 347 353.
66. Tank J, Schroeder C, Diedrich A, Szczech E, Haertter S, Sharma AM, Luft FC, Jordan J. Selective impairment in sympathetic vasomotor control with norepinephrine transporter inhibition. Circulation 2003 107 : 2949 2954.
67. Preiss G, Polosa C. Patterns of sympathetic neuron activity associated with Mayer waves. Am J Physiol 1974 226 : 724 730.
68. Furlan R, Porta A, Costa F, Tank J, Baker L, Schiavi R, Robertson D, Malliani A, Mosqueda-Garcia R. Oscillatory patterns in sympathetic neural discharge and cardiovascular variables during orthostatic stimulus. Circulation 2000 101 : 886 892.
69. Eisenhofer G, Saigusa T, Esler MD, Cox HS, Angus JA, Dorward PK. Central sympathoinhibition and peripheral neuronal uptake blockade after desipramine in rabbits. Am J Physiol 1991 260 : R824 R832.
70. Grassi G, Seravalle G, Cattaneo BM, Bolla GB, Lanfranchi A, Colombo M, Giannattasio C, Brunani A, Cavagnini F, Mancia G. Sympathetic activation in obese normotensive subjects. Hypertension 1995 25 : 560 563.
71. Scholze J. [Sibutramine in clinical practice - a PMS-study with positive effects on blood pressure and metabolic parameters] (article in German). Dtsch Med Wochenschr 2002 127 : 606 610.
72. Kolanowski J. A risk-benefit assessment of anti-obesity drugs. Drug Saf 1999 20 : 119 131.
73. Guven A, Koksal N, Cetinkaya A, Sokmen G, Ozdemir R. Effects of the sibutramine therapy on pulmonary artery pressure in obese patients. Diabetes Obes Metab 2004 6 : 50 55.
74. Bach DS, Rissanen AM, Mendel CM, Shepherd G, Weinstein SP, Kelly F, Seaton TB, Patel B, Pekkarinen TA, Armstrong WF. Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obes Res 1999 7 : 363 369.
75. Coulter D. The New Zealand Intensive Medicines Monitoring Programme in pro-active safety surveillance. Pharmacoepidemiol Drug Saf 2000 9 : 273 280.
76. Harrison-Woolrych M, Clark DW, Hill GR, Rees MI, Skinner JR. QT interval prolongation associated with sibutramine treatment. Br J Clin Pharmacol 2006 61 : 464 469.
77. Escande D. Pharmacogenetics of cardiac K (+) channels. Eur J Pharmacol 2000 410 : 281 287.
78. Sayin T, Guldal M. Sibutramine: possible cause of a reversible cardiomyopathy. Int J Cardiol 2005 99 : 481 482.
79. Wooltorton E. Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. CMAJ 2002 166 : 1307 1308.
80. Narkiewicz K. Sibutramine and its cardiovascular profile. Int J Obes Relat Metab Disord 2002 26 : S38 S41.
81. Taflinski T, Chojnacka J. Sibutramine-associated psychotic episode. Am J Psychiatry 2000 157 : 2057 2058.
82. Binkley K, Knowles SR. Sibutramine and panic attacks. Am J Psychiatry 2002 159 : 1793 1794.
83. Fernandez P, Peiro AM. A sibutramine-induced delusional disorder relapse. J Neuropsychiatry Clin Neurosci 2007 19 : 88 89.
84. Cordeiro Q, Vallada H. Sibutramine-induced mania episode in a bipolar patient. Int J Neuropsychopharmacol 2002 5 : 283 284.
85. Clark DW, Harrison-Woolrych M. Sibutramine may be associated with memory impairment. BMJ 2004 329 : 1316.
86. Buhot MC, Martin S, Segu L. Role of serotonin in memory impairment. Ann Med 2000 32 : 210 221.
87. Meridia (Sibutramine Hydrochloride Monohydrate) drug description - prescription drugs and medications at RxList. [WWW document]. URL http://www.rxlist.com/cgi/generic/sibutramine.htm (accessed June 2007).
88. Chounta A, Tsiodras S, Zouridakis S, Doumas M, Giamarellou H. Sibutramine use associated with reversible hepatotoxicity. Ann Intern Med 2005 143 : 763 764.
89. Luque CA, Rey JA. Sibutramine. a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann Pharmacother 1999 33 : 968 978.
90. Giese SY, Neborsky R. Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl. Plast Reconstr Surg 2001 107 : 293 294.
91. Nelson SM, Fleming RF. The preconceptual contraception paradigm: obesity and infertility. Hum Reprod 2007 22 : 912 915.
92. Rockville, MD: Food and Drug Administration. FDA advising risk of birth defects with Paxil: agency requiring updated product labelling. 8 December 2005. [WWW document]. URL http://www.fda.gov/bbs/topics/NEWS//NEW01270.html (accessed June 2007).
93. Ottawa: Health Canada. Use of paroxetine in first trimester of pregnancy may have a small increased risk of birth defects, compared to other antidepressants. October 2005. [WWW document]. URL http://hc-sc.gc.ca/dhp-mps/ medeff/advisories-avis/public//paxil_3_pa-ap_e.html (accessed June 2007)
94. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007 356 : 2675 2683.
95. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007 356 : 2684 2692.